Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shanghai HeartCare Medical Technology's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:06609'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -93.12 Med: -15.63 Max: 8.18
Current: 8.01
During the past 7 years, Shanghai HeartCare Medical Technology's highest Return-on-Tangible-Equity was 8.18%. The lowest was -93.12%. And the median was -15.63%.
HKSE:06609's Return-on-Tangible-Equity is ranked better than 58.6% of 756
companies
in the Medical Devices & Instruments industry
Industry Median: 4.965
vs HKSE:06609: 8.01
Shanghai HeartCare Medical Technology (HKSE:06609) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shanghai HeartCare Medical Technology Return-on-Tangible-Equity Related Terms
Shanghai HeartCare Medical Technology Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai HeartCare Medical Technology Return-on-Tangible-Equity Chart
HKSE:06609 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai HeartCare Medical Technology Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai HeartCare Medical Technology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.02% mean?
Shanghai HeartCare Medical Technology (HKSE:06609) has a Return-on-Tangible-Equity of 6.02% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai HeartCare Medical Technology and its competitors. According to the industry distribution chart, Shanghai HeartCare Medical Technology ranks #313 out of 756 companies in the Medical Devices & Instruments industry, placing it in the top 41.4%.
Is Shanghai HeartCare Medical Technology's Return-on-Tangible-Equity too high?
Shanghai HeartCare Medical Technology's current Return-on-Tangible-Equity is 6.02%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.97. Shanghai HeartCare Medical Technology's value of 6.02% is 21.2% above this industry median. Based on the distribution chart, Shanghai HeartCare Medical Technology ranks #313 out of 756 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shanghai HeartCare Medical Technology has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai HeartCare Medical Technology's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai HeartCare Medical Technology ranks #313 out of 756 companies for Return-on-Tangible-Equity. This puts Shanghai HeartCare Medical Technology in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.97. Shanghai HeartCare Medical Technology's value of 6.02% is 21.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.97, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai HeartCare Medical Technology's current Return-on-Tangible-Equity of 6.02% is 21.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai HeartCare Medical Technology and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai HeartCare Medical Technology's current Return-on-Tangible-Equity is 6.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai HeartCare Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology (HKSE:06609) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$54.80, compared to a current price of HK$48.24 — trading 12% below its estimated fair value. The current Return-on-Tangible-Equity is 6.02% and 21.2% above the Medical Devices & Instruments industry median of 4.97. Shanghai HeartCare Medical Technology's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shanghai HeartCare Medical Technology (HKSE:06609), the current Return-on-Tangible-Equity is 6.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai HeartCare Medical Technology (HKSE:06609) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai HeartCare Medical Technology stock appears to be undervalued.
The current stock price of HK$48.24 is trading 12% below its estimated GF Value™ of HK$54.80.
GuruFocus considers Shanghai HeartCare Medical Technology to be Modestly Undervalued.
Key valuation signals for HKSE:06609:
Return-on-Tangible-Equity: 6.02%
GF Value™: HK$54.80 vs. price of HK$48.24 (12% below fair value)
Industry Position: 21.2% above the Medical Devices & Instruments median (#313 of 756)
No single metric tells the full story. See the HKSE:06609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai HeartCare Medical Technology Corp Ltd is an neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. The company focuses on Research and development, manufacturing and commercialization to fulfill the unmet needs of clinicians and patients to redefine the standard of care, reduce mortality rate, and improve prognosis by continuously launching new medical devices. Geographically, the Group's majority revenue is derived from Chinese Mainland.
78GF Score
Get the complete analysis for HKSE:06609
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06609 has been successfully added to your 
